Shareholders with more than 5%:

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying medical innovation and investing in the creation and growth of companies developing these assets into differentiated products that will make a difference to patients’ lives and provide an attractive return on investment to its shareholders. Karolinska Development has access to world-class medical innovations at leading universities and research institutes in the Nordic region, including the Karolinska Institutet. The Company aims to build companies around innovative products and technologies, supported by experienced management teams and advisers, and co-funded by specialist international life science investors, to provide the greatest chance of success. Karolinska Development’s portfolio comprises 10 companies focusing on the development of innovative treatment for life-threatening or serious debilitating diseases. The Company is led by a team of investment professionals with strong investment backgrounds, experienced company builders and entrepreneurs, with access to a strong global network. For more information, please visit

About The Foundation for Baltic and East European Studies (Östersjöstiftelsen) 

Östersjöstiftelsen (the Foundation for Baltic and East European Studies) was founded by the Swedish government in 1994 to support research, doctoral studies and academic infrastructure at Södertörn University. Östersjöstiftelsen has funded approximately 200 research projects and the education of 140 doctoral students at Södertörn University. From 2000 to 2016, Södertörn University has been granted funds totalling SEK 3.2 billion. In September 2016, the Foundation managed assets totaling over SEK 5 billion.

About Praktikerinvest PE AB

Praktikerinvest is an investment company owned by Praktikertjänst AB, the largest private health and dental care provider in Sweden. Praktikerinvest invests primarily in private equity and real estate.

About Rosetta Capital

Rosetta is a UK-based global venture capital company focused on direct secondary transactions in the life science space. Rosetta has five funds under management. A multinational team with backgrounds in venture capital, pharmaceutical and biotechnology, Rosetta works with inventors, entrepreneurs and international investors in often game-changing companies. Rosetta has successfully taken many of its portfolio companies to IPOs and trade sales.

About Lee’s Healthcare Fund

Lee’s Healthcare Industry Fund L.P. (“Lee’s Fund”), is an investment fund established in the Cayman Islands in August 2015 with the principal objective to invest in privately held companies in the biomedical sectors in the United States of America, Europe and Asia, including but not limited to the areas of pharmaceuticals, biologics, diagnostics and medical devices. Lee's Pharmaceutical Holdings Limited (SEHK Stock Code: 950), a research-based, biopharmaceutical company listed in Hong Kong with over 20 years of operation in China's pharmaceutical industry, is one of the Limited Partners of Lee’s Fund.

About Opocrin SpA

Established in 1964, Opocrin SpA is a world leader in the research, production and marketing of APIs from biologically derived sources. Through studying and processing heparins and its derivatives over a period years, Opocrin has gained competence and expertise in the field of thrombosis, cardiovascular and hematopoietic diseases and in the chemistry of polysaccharides in general. Since the beginning, the Opocrin R&D team has developed numerous products that are approved by the scientific community and marketed by important pharmaceutical companies worldwide.